Level Four Advisory Services LLC Has $458,000 Stake in Tempus AI, Inc. $TEM

Level Four Advisory Services LLC cut its holdings in shares of Tempus AI, Inc. (NASDAQ:TEM) by 64.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,677 shares of the company’s stock after selling 10,289 shares during the quarter. Level Four Advisory Services LLC’s holdings in Tempus AI were worth $458,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the company. Vanguard Group Inc. lifted its stake in Tempus AI by 22.1% during the third quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock worth $762,032,000 after purchasing an additional 1,706,837 shares during the period. AQR Capital Management LLC bought a new position in Tempus AI in the second quarter valued at about $54,020,000. Geode Capital Management LLC boosted its stake in Tempus AI by 411.4% in the second quarter. Geode Capital Management LLC now owns 649,420 shares of the company’s stock valued at $41,264,000 after acquiring an additional 522,443 shares during the last quarter. Legal & General Group Plc boosted its holdings in Tempus AI by 24.4% during the second quarter. Legal & General Group Plc now owns 450,645 shares of the company’s stock worth $28,634,000 after buying an additional 88,373 shares during the last quarter. Finally, Marex Group plc bought a new position in shares of Tempus AI during the second quarter worth $26,620,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Trading Down 1.5%

TEM opened at $52.26 on Friday. Tempus AI, Inc. has a twelve month low of $36.22 and a twelve month high of $104.32. The company has a fifty day moving average of $60.14 and a 200-day moving average of $72.59. The stock has a market cap of $9.30 billion, a PE ratio of -37.06 and a beta of 5.29. The company has a quick ratio of 3.00, a current ratio of 3.13 and a debt-to-equity ratio of 2.52.

Insider Buying and Selling at Tempus AI

In other Tempus AI news, EVP Andrew Polovin sold 10,949 shares of the business’s stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $60.31, for a total transaction of $660,334.19. Following the completion of the sale, the executive vice president directly owned 126,918 shares of the company’s stock, valued at approximately $7,654,424.58. The trade was a 7.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Ryan Fukushima sold 9,592 shares of the stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $59.05, for a total value of $566,407.60. Following the completion of the sale, the chief executive officer directly owned 694,354 shares of the company’s stock, valued at $41,001,603.70. The trade was a 1.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 590,109 shares of company stock valued at $37,056,566 over the last ninety days. Insiders own 26.27% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on TEM. Stifel Nicolaus set a $60.00 price target on shares of Tempus AI in a research note on Wednesday, February 25th. Canaccord Genuity Group lowered their price objective on shares of Tempus AI from $95.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, December 22nd. Morgan Stanley cut their price objective on Tempus AI from $85.00 to $70.00 and set an “overweight” rating for the company in a research report on Tuesday. Needham & Company LLC cut their price target on Tempus AI from $100.00 to $75.00 and set a “buy” rating for the company in a report on Wednesday, February 25th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Tempus AI from $80.00 to $60.00 and set a “neutral” rating on the stock in a report on Wednesday, February 25th. Eight equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $78.15.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.